Loading...
Market
Story
Medicare to Cover Eli Lilly's Zepbound for Sleep Apnea Following FDA Approval
Jan 8, 2025, 08:34 PM
The Centers for Medicare & Medicaid Services (CMS) has announced that Medicare will cover Eli Lilly's Zepbound for the treatment of obstructive sleep apnea (OSA). This decision follows the drug's recent FDA approval, making Zepbound the first medication specifically approved for moderate-to-severe OSA. The coverage under Medicare Part D is expected to enhance the drug's market potential, as it is already recognized as a significant treatment option for obesity-related conditions.
View original story
Similar markets
Yes • 50%
No • 50%
Medicines and Healthcare products Regulatory Agency (MHRA) • 25%
European Medicines Agency (EMA) • 25%
Other • 25%
Therapeutic Goods Administration (TGA) • 25%
Less than 5 • 25%
11 to 15 • 25%
More than 15 • 25%
5 to 10 • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
United Kingdom • 25%
Australia • 25%
Other • 25%
European Union • 25%
